MoonLake Immunotherapeutics
MLTXNASDAQHealthcare● Active
$18.08
+$0.18(+0.98%)
Market Cap$1.3B
P/E Ratio—
52W High$62.75
52W Low$5.95
MoonLake Immunotherapeutics (MLTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MLTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.98
Est. -$0.91 · -7.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS
MLTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.93 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.91 | -$0.98 | -7.7% | — | — | — |
| — Q1 FY2026 | Feb 25, 2026 | -$0.92 | -$0.92 | +0.0% | — | — | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.89 | -$1.10 | -23.6% | — | — | — |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.73 | -$0.87 | -19.2% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.76 | -$0.63 | +17.1% | — | — | — |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.53 | -$0.72 | -35.9% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.44 | -$0.56 | -27.3% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.93
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.98
EPS Est.
-$0.91
EPS Surpr.
-7.7%
Revenue
—
Q1 FY2026
Feb 25, 2026
EPS Actual
-$0.92
EPS Est.
-$0.92
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$1.10
EPS Est.
-$0.89
EPS Surpr.
-23.6%
Revenue
—
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.87
EPS Est.
-$0.73
EPS Surpr.
-19.2%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.63
EPS Est.
-$0.76
EPS Surpr.
+17.1%
Revenue
—
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.72
EPS Est.
-$0.53
EPS Surpr.
-35.9%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.56
EPS Est.
-$0.44
EPS Surpr.
-27.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.89 | $-0.89 | $-0.89 | 2 |
| Q3 FY2027 | $-1.02 | $-1.02 | $-1.02 | 1 |
| Q2 FY2027 | $-0.98 | $-0.98 | $-0.98 | 1 |
| Q1 FY2027 | $-1.01 | $-1.01 | $-1.01 | 2 |
| Q4 FY2026 | $-0.93 | $-0.93 | $-0.93 | 2 |
| Q3 FY2026 | $-1.06 | $-0.94 | $-0.75 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -7.7% | $17.06 | $18.84 | +10.43% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +0.0% | $18.20 | $18.22 | +0.11% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -23.6% | $10.13 | $10.59 | +4.54% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -19.2% | $53.32 | $53.41 | +0.17% |
| ▲ Q2 FY2025 | May 12, 2025 | +17.1% | $38.47 | $40.18 | +4.45% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -35.9% | $40.73 | $42.37 | +4.03% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -27.3% | $51.48 | $50.67 | -1.57% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -39.3% | $43.93 | $43.06 | -1.98% |
Q2 FY2026+10.43%
Report Date
May 11, 2026
EPS Beat/Miss
-7.7%
Price Before
$17.06
Price After
$18.84
Q1 FY2026+0.11%
Report Date
Feb 25, 2026
EPS Beat/Miss
+0.0%
Price Before
$18.20
Price After
$18.22
Q4 FY2025+4.54%
Report Date
Nov 5, 2025
EPS Beat/Miss
-23.6%
Price Before
$10.13
Price After
$10.59
Q3 FY2025+0.17%
Report Date
Aug 5, 2025
EPS Beat/Miss
-19.2%
Price Before
$53.32
Price After
$53.41
Q2 FY2025+4.45%
Report Date
May 12, 2025
EPS Beat/Miss
+17.1%
Price Before
$38.47
Price After
$40.18
Q1 FY2025+4.03%
Report Date
Feb 26, 2025
EPS Beat/Miss
-35.9%
Price Before
$40.73
Price After
$42.37
Q4 FY2024-1.57%
Report Date
Nov 7, 2024
EPS Beat/Miss
-27.3%
Price Before
$51.48
Price After
$50.67
Q3 FY2024-1.98%
Report Date
Aug 7, 2024
EPS Beat/Miss
-39.3%
Price Before
$43.93
Price After
$43.06
Avg Beat Reaction+2.28%
Avg Miss Reaction+2.60%
Beat Rate2 / 8 quarters
Largest Move+10.43% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MLTX ends December
MoonLake Immunotherapeutics (MLTX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.98 — missing the analyst consensus of $-0.91 by -7.7%. The next MLTX earnings date is expected around September 1, 2026.
Each quarter, investors track MLTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MLTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MLTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MLTX earnings · 5 questionsMoonLake Immunotherapeutics's next earnings report is expected around September 1, 2026. MLTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MLTX historically reports after market close (AMC).
MLTX earnings datewhen is MLTX earningsMLTX next earnings datewhen does MLTX report earningsMLTX earnings calendar
▸ Source: FMP · MoonLake Immunotherapeutics SEC filings · US GAAP · MoonLake Immunotherapeutics SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026